89bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2024:

• Wells Fargo 2024 Healthcare Conference on September 5 at 12:45 PM ET (Fireside Chat)
• H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 11:30 AM ET (Presentation)
• 2024 Cantor Global Healthcare Conference on September 17 at 11:30 AM ET (Fireside Chat)

Webcasts of these presentations will be available on 89bio's website, with replays accessible for approximately 30 days after each conference.

News Market Reaction

+2.56%

1 alert

+2.56% News Effect

On the day this news was published, ETNB gained 2.56%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of September:

Wells Fargo 2024 Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 5, 2024
Time: 12:45 PM ET

H.C. Wainwright 26^th Annual Global Investment Conference
Format: Presentation
Date: Monday, September 9, 2024
Time: 11:30 AM ET

2024 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 17, 2024
Time: 11:30 AM ET

Webcasts of these presentations will be accessible in the investor section of 89bio’s website. A replay of each webcast will be available for approximately 30 days following the conference.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang 
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

Media Contact: 
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com

FAQ

What investor conferences will 89bio (ETNB) attend in September 2024?

89bio (ETNB) will participate in three investor conferences in September 2024: Wells Fargo Healthcare Conference on September 5, H.C. Wainwright Global Investment Conference on September 9, and Cantor Global Healthcare Conference on September 17.

When is 89bio's (ETNB) presentation at the Wells Fargo 2024 Healthcare Conference?

89bio (ETNB) will participate in a fireside chat at the Wells Fargo 2024 Healthcare Conference on Thursday, September 5, 2024, at 12:45 PM ET.

What type of presentation will 89bio (ETNB) give at the H.C. Wainwright conference?

89bio (ETNB) will give a presentation at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 11:30 AM ET.

How can investors access 89bio's (ETNB) conference presentations?

Investors can access webcasts of 89bio's (ETNB) conference presentations in the investor section of the company's website. Replays will be available for approximately 30 days following each conference.

What is the focus of 89bio's (ETNB) clinical research?

89bio (ETNB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of liver and cardiometabolic diseases.